Highlights CervoMed Inc.

Equities

CRVO

US15713L1098

Market Closed - Nasdaq Other stock markets 03:57:46 2024-05-29 pm EDT			5-day change	1st Jan Change
20.1 ^USD	+10.32%		+5.73%	+163.43%

01:39pm	JonesTrading Starts CervoMed With Buy Rating, $70 Price Target	MT
May. 20	CervoMed Names William Elder CFO	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Earnings Flash (CRVO) CERVOMED Posts Q1 Revenue $2.3M	May. 15	MT
CervoMed Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 29	CI
Cervomed Inc. Publishes Positive Results from AscenD-LB Phase 2a Trial in Peer-Reviewed Journal That Supports the Therapeutic Potential of Neflamapimod in Dementia with Lewy Bodies	Feb. 12	CI
CervoMed Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 13	CI
CervoMed Inc. Announces Oral Presentation at CTAD 2023 Highlighting Phase 2b Neflamapimod Program for the Treatment of Patients with Dementia with Lewy Bodies	23-10-18	CI
CervoMed Inc. Announces Publication in Neurology® Results Showing A Blood Test At Study Entry Identified Patients Who Demonstrated Substantial Response to Neflamapimod in Dementia with Lewy Bodies	23-09-06	CI
Reverse Split: 1 of 1.5	23-08-16	FA

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

+201.5% on SUPER MICRO COMPUTER since our purchase on February 17, 2023

Replicate our performance

fermer